CD276 and neoplasm: To evaluate the antitumor activity of B7-H3.CAR-T cells against human NSCLC, five B7-H3+ human NSCLC cell lines (A549, H1299, H460, H520, and SK-MES-1) were cocultured with control CD19.28, B7-H3.28 or B7-H3.BB CAR-T cells at T cell to tumor cell ratio of 1:5 (Fig. 1c).